Comparative Pharmacology
Head-to-head clinical analysis: GENTAFAIR versus NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE.
Head-to-head clinical analysis: GENTAFAIR versus NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE.
GENTAFAIR vs NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gentamicin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and causing misreading of mRNA, leading to cell death.
Neomycin and polymyxin B sulfates are aminoglycoside and polypeptide antibiotics, respectively, that inhibit bacterial protein synthesis and disrupt bacterial cell membrane integrity. Dexamethasone is a corticosteroid that suppresses inflammation by inhibiting phospholipase A2, reducing prostaglandin and leukotriene synthesis.
Gentamicin 3-5 mg/kg IV or IM once daily for serious infections; alternatively, 1.5-2 mg/kg IV or IM every 8 hours.
Ophthalmic: 1-2 drops in affected eye(s) every 3-4 hours; severe infections: 1-2 drops every 1-2 hours, then taper. Otic: 3-4 drops in affected ear(s) 3-4 times daily.
None Documented
None Documented
2-3 hours (normal renal function); may extend to 24-48 hours in severe renal impairment, necessitating dose adjustment.
Neomycin: 2-3 hours (IM/IV, if absorbed); Polymyxin B: 6-7 hours; Dexamethasone: 3-4.5 hours. Clinically, neomycin's half-life is not relevant due to minimal absorption; polymyxin B prolonged in renal impairment; dexamethasone CNS effect lasts > half-life.
Renal: over 90% unchanged via glomerular filtration; minor biliary (<1%).
Neomycin: ~99% of oral dose eliminated unchanged in feces; <1% absorbed renally excreted. Polymyxin B: ~60% renal elimination of absorbed fraction; remainder non-renal via biliary/fecal. Dexamethasone: ~65% renal as metabolites, <10% unchanged; ~35% fecal.
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic